Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Want to see NAUT full AI Analyst Report?
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▼(-17.49% Downside)
Action:Reiterated
Date:06/02/26
The score is held back primarily by weak financial performance (no revenue, large ongoing losses, and meaningful cash burn), partially offset by a constructive earnings call that showed tangible technical/commercial progress, cost discipline, and a stated cash runway through 2027. Technical indicators are broadly neutral and valuation is difficult to support due to negative earnings and no stated dividend yield.
Positive Factors
Differentiated Proteomics Capability
Unique single-molecule proteoform insights demonstrated in collaborator studies create durable scientific differentiation. These proprietary data types can drive publications, high-value collaborations, and a defensible moat for assays, supporting long-term demand from discovery and pharma R&D.
Negative Factors
No Revenue & Large Losses
Persistent lack of product revenue and sizable operating losses reflect a pre‑commercial business model. Until recurring instrument, consumable, or service sales materialize, the company cannot demonstrate sustainable unit economics or operating leverage, leaving economics dependent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated Proteomics Capability
Unique single-molecule proteoform insights demonstrated in collaborator studies create durable scientific differentiation. These proprietary data types can drive publications, high-value collaborations, and a defensible moat for assays, supporting long-term demand from discovery and pharma R&D.
Read all positive factors
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.66M
Dividend YieldN/A
Average Volume (3M)394.63K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth17.33%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding127,078,860
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-118.29
Enterprise Value/Ebitda-7.14
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$700.00K
Nautilus Biotechnolgy Business Overview & Revenue Model
Company Description
Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus P...
How the Company Makes Money
null...
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call emphasized substantive technical and commercial progress: verified service lab, strong scientific collaborator results (including novel ApoE–Tau proteoform findings), nearly tripled qualified probes, targeted oncology assay progress, and deliberate commercial hires. Financially the company reduced operating expenses YoY and exited the quarter with $143.4M in cash and a stated runway through 2027. Offsetting these positives are external delays (Middle East conflict) that pushed grant revenue recognition and some reagent development later in the year, a nascent sales pipeline with only one named EAP customer so far, remaining verification/validation work before broadscale customer deployments, and modest expected revenue (~$0.5M) for 2026. On balance, accomplishments materially outweigh the challenges but execution and timing risks remain.Positive Updates
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Negative Updates
Revenue and Grant Recognition Delays
Revenue recognition tied to the Michael J. Fox Foundation grant progressed more slowly than anticipated due to delays related to the ongoing conflict in the Middle East; company now expects approximately $0.5M in total revenue for the year with a greater portion shifting into later quarters.
Read all updates
Q1-2026 Updates
Positive
Negative
Early Access Program Launch and Strategic Collaborations
Launched Iterative Mapping Early Access Program in January 2026 and debuted the Voyager platform at US HUPO; established collaborations including the Michael J. Fox Foundation/Weill Cornell Medicine-Qatar alpha-synuclein program and ongoing work with Buck Institute and Allen Institute, enabling unique proteoform-level biological insights.
Read all positive updates
Company Guidance
Nautilus reiterated a detailed commercialization timetable and metric-backed progress: it plans to expand Iterative Mapping Early Access in H2 2026 with a second (oncology) proteoform assay, introduce broadscale capabilities into early access later in 2026, begin beta Voyager placements in late Q3/Q4 2026, open preorders in late 2026 with customer installations starting in early 2027 and general availability of broadscale capabilities in H1 2027. Operationally, the company has one named EAP customer (Baylor College of Medicine), active collaborations with the Buck Institute, Allen Institute and Neural Stem Cell Institute, an Alpha instrument in the field for ~1 year, a sales team of three (VP Amber Faust +2 hires), a service lab that passed verification/validation (meeting accuracy, dynamic range, reproducibility and stability requirements), nearly tripled the number of probes qualified as assay-compatible this quarter and completed its largest number of high‑cycle decode experiments while routinely testing lysate mixtures and full lysates. Financially, Q1 operating expenses were $16.1M (R&D $9.7M, down 16% Y/Y; G&A $6.4M, down 12% Y/Y), Q1 cash burn was $12.8M (including $1.1M from option exercises), cash and investments were $143.4M at quarter end, management expects roughly $0.5M revenue for the year (shifted into later quarters) and believes the cash runway extends through 2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.06M | -6.46M | -6.35M | -5.71M | -3.42M | -2.84M |
| EBITDA | -50.77M | -52.54M | -64.43M | -61.83M | -54.51M | -47.47M |
| Net Income | -57.09M | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | ||||||
| Total Assets | 177.78M | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 95.87M | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 28.87M | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 33.36M | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 144.41M | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | ||||||
| Free Cash Flow | -51.43M | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -49.86M | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 29.95M | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 1.30M | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Technical Analysis
Negative
3.03
Price Trends
2.73
Negative
2.66
Negative
2.06
Positive
Market Momentum
-0.12
Positive
37.66
Neutral
3.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 3.03 is above the 20-day moving average (MA) of 2.48, above the 50-day MA of 2.73, and above the 200-day MA of 2.06, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 37.66 is Neutral, neither overbought nor oversold. The STOCH value of 3.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 68 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $284.66M | -4.97 | -35.04% | ― | ― | 17.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $22.83M | -0.36 | ― | ― | ― | ― | |
46 Neutral | $94.51M | -2.33 | -72.78% | ― | ― | 73.91% | |
46 Neutral | $95.14M | -1.37 | -26.58% | ― | -1.44% | 11.50% | |
45 Neutral | $171.18M | -1.32 | -123.07% | ― | ― | 3.91% |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
2.24
1.52
211.11%
VTGN
VistaGen Therapeutics
0.58
-1.78
-75.59%
KLRS
Kalaris Therapeutics
4.33
1.66
62.17%
SEER
Seer
1.72
-0.30
-14.85%
ABOS
Acumen Pharmaceuticals
2.37
1.23
107.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.